

## An overview of therapeutic approaches to brain tumor stem cells

Alireza Khoshnevisan<sup>1</sup>

*Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.*

Received: 1 January 2012

Revised: 14 February 2012

Accepted: 18 February 2012

### Abstract

Primary and secondary malignant central nervous system (CNS) tumors are devastating invasive tumors able to give rise to many kinds of differentiated tumor cells. Glioblastoma multiform (GBM), is the most malignant brain tumor, in which its growth and persistence depend on cancer stem cells with enhanced DNA damage repair program that also induces recurrence and resists current chemo- and radiotherapies. Unlike non-tumor stem cells, tumor stem cells lack the normal mechanisms that regulate proliferation and differentiation, resulting in uncontrolled production and incomplete differentiation of tumor cells. In current paper recent developments and new researches in the field of brain tumor stem cells have been reviewed.

**Keywords:** Brain tumor, Stem cells, Glioma.

### Introduction

Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS). The prognoses for these tumors are related to several factors, such as the age of the patient, and the location and histology of the tumor. In adults, about half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are malignant. For most benign CNS tumors that require treatment, we can offer curative resections or at least provide significant relief from mass effect. Unfortunately, we still lack effective treatments for most primary and secondary malignant CNS tumors. However, the past decade has witnessed an explosion in the understanding of the early molecular events in malignant primary CNS tumors, and for the first time in history, oncologists are seeing that a plethora of new therapies target-

ing these molecular events are being tested in clinical trials. There is hope on the horizon for the fight against these deadly tumors (1). Over the past few years, the traditional view of brain tumorigenesis has been revolutionized by advances in genomic medicine, molecular biology, stem cell biology, and genetically-engineered small-animal modeling (2,3). The concept of cancer stem-like cells (CSCs) has gained considerable attention in various solid tumors including glioblastoma (GBMs) (4,5). Glioblastomas are the most common primary brain tumors with poor prognosis (6). CD133, nestin and recently CD90 (7) have been considered the putative markers of (CSCs) in malignant cancers, including GBMs. Unlike non-tumor stem cells, tumor stem cells lack the normal mechanisms that regulate proliferation and differentiation, resulting in uncontrolled production and incomplete differentiation of tumor cells

1. **(Corresponding author)** Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. akhoshnevisan@yahoo.com

(8,9). Some data suggest that CD133(+) glioma stem cells (GSCs) exhibit more aggressive invasion in vitro and GSCs in vivo probably disseminate along the long axis of blood vessels and transit through the white matter tracts (10,11). Recent studies have suggested that cancer stem cells cause tumor recurrence based on their resistance to radiotherapy and chemotherapy (12,13). This sub-population of tumor cells has been intensively investigated and their role in therapy resistance as well as tumor recurrence has been demonstrated. In that respect, development of therapeutic strategies that target CSCs (and possibly also the tumor bulk) appears a promising approach for patients suffering from primary brain tumors. Here we explored new researches that have been conducted in the field of brain tumor stem cells.

### Review of literature

#### *In vivo evidences for glioblastoma cancer stem cells*

In order to test the relative tumorigenicity of CSCs and non-stem tumor cells in the same microenvironment, matched tumor populations were purified from a primary human tumor transplanted into a xenograft mouse model and competitive in vivo tumor growth studies using serial in vivo intravital microscopy were monitored. While CSCs were a small minority of the initial transplanted cancer cell population, the CSCs, not the non-stem tumor cells, drove tumor formation and yielded tumors displaying a cellular hierarchy. It has been found that in the resulting tumors, a fraction of the initial transplanted CSCs maintained expression of stem cell and proliferation markers, which were significantly higher compared to the non-stem tumor cell population and this evidence shows that CSCs generated cellular heterogeneity within the tumor (14,15). These comparisons between matched CSCs and non-stem tumor cells provide the first functional evidence using live imaging that in the same microenvironment, CSCs more than non-stem tumor cells are responsible for tumor propagation, confirming the func-

tional definition of a CSC.

#### *MicroRNA-34a is tumor suppressive in brain tumors and glioma stem cells*

MicroRNAs (miRNAs) are evolutionarily conserved, endogenous, small, non-coding RNA molecules of about 22 nucleotides in length that function as posttranscriptional gene regulators. They are deemed to play a crucial role in the initiation and progression of human cancer, and those with a role in cancer are designated as oncogenic miRNAs (oncomiRs) (16,17,18). Recently it has been found that microRNA-34a (miR-34a) is downregulated in human glioma tumors as compared to normal brain, and that miR-34a levels in mutant-p53 gliomas were lower than in wildtype-p53 tumors. This finding shows that miR-34a is a potential tumor suppressor in brain tumors that acts by targeting multiple oncogenes (19). The new data show that miR-34a expression inhibits various malignancy endpoints in glioma stem cells. Importantly, it has been shown for the first time that miR-34a expression induces glioma stem cell differentiation (20). MicroRNA (miRNA)-34a (1p36.23) is generally expressed at lower levels in unfavorable primary neuroblastoma (NB) tumors and cell lines relative to normal adrenal tissue and reintroduction of this miRNA into three different NB cell lines causes a dramatic reduction in cell proliferation through the induction of a caspase-dependent apoptotic pathway. Altogether, the data suggest that miR-34a is a tumor suppressor and a potential potent therapeutic agent that acts by targeting multiple oncogenic pathways in brain tumors and by inducing the differentiation of cancer stem cells.

Nonetheless, the microRNA145 with cationic polyurethane-short branch PEI to inhibit cancer stem cell-like properties

It has been shown that expression of miR145 (a tumor-suppressive miRNA) is inversely correlated with the levels of Oct4 and Sox2 (SRY (sex determining region Y)-box 2, also known as SOX2, is a transcription factor that is essential to maintain self-

renewal of undifferentiated embryonic stem cells) in GBM-CD133(+) cells and malignant glioma specimens. It has been demonstrated that miR145 negatively regulates GBM tumorigenesis. Using polyurethane-short branch polyethylenimine (PU-PEI) as a therapeutic-delivery vehicle, PU-PEI-mediated miR145 delivery to GBM-CD133(+) significantly inhibits their tumorigenic and CSC-like abilities. Furthermore, PU-PEI-miR145-treated GBM-CD133(+) effectively suppresses the expression of drug-resistance and anti-apoptotic genes and increases the sensitivity of the cells to radiation and temozolomide. Finally, the in vivo delivery of PU-PEI-miR145 alone significantly suppresses tumorigenesis with stemness, and improves the survival rate when used in combination with radiotherapy and temozolomide in mice (21,22). Expression of Sox2 at transcriptional level has also been reported to decrease during arsenic trioxide [As(2)O(3)]-induced glioma cell apoptosis (23,24). Therefore, PU-PEI-miR145 and arsenic trioxide can be a novel therapeutic approach for malignant brain tumors.

#### *Glioma tumor suppression by Pro-neural miR-128*

The MiR-128 represses glioma-initiating neural stem cells (giNSCs) growth by enhancing neuronal differentiation. The MiR-128 represses growth and mediates differentiation by targeting oncogenic receptor tyrosine kinases (RTKs) epithelial growth factor receptor and platelet-derived growth factor receptor- $\alpha$ . Using an autochthonous glioma mouse model, it has been demonstrated that miR-128 repressed gliomagenesis (25). MiR-128 has been identified as a glioma tumor suppressor that targets receptor tyrosine kinases (RTK) signaling to repress giNSC self-renewal and enhance differentiation.

#### *Correlation between tumor vascular niche and glioblastoma stem cells*

It is believed that formation of abnormal, dysfunctional tumor vasculature and

glioblastoma stem-like cells (GSCs) are the major obstacles to treat these tumors effectively. Brain tumor stem cell markers CD133 and nestin are expressed in tumor and endothelial cells in GBM samples. Double immunofluorescence stainings showed that the two different marked GSCs were found accumulated around the CD31+ blood vessels and CD133/CD31 or nestin/CD31 co-expression was found in the endothelial cells and GSCs. Additionally, the vascular endothelial growth factor (VEGF) and the endothelial marker CD31 were co-expressed in GSCs (26,27). These findings demonstrate that GSCs contribute directly to the tumor vasculature by endothelial cell differentiation, and a significant portion of the vascular endothelium has a neoplastic origin and therefore GSCs and tumor vascularization are closely related to each other, not only in the regional distribution but also in biological function (28,29). These evidences show a new mechanism for tumor vasculo-genesis and may provide new insights for targeted therapy against brain tumors.

NOTCH ligands that are provided by endothelial cells create a stem cell niche in glioblastoma. NOTCH ligands (The notch receptor is a single-pass transmembrane receptor protein. It is a hetero-oligomer composed of a large extracellular portion, which associates in a calcium-dependent, non-covalent interaction with a smaller piece of the notch protein composed of a short extracellular region, a single transmembrane-pass, and a small intracellular region) are expressed in endothelial cells adjacent to nestin and NOTCH receptor-positive cancer cells in primary GBMs (30,31). Coculturing human brain microvascular endothelial cells (hBMEC) or NOTCH ligand with GBM neurospheres promoted GBM cell growth and increased CSLC self-renewal. RNAi-mediated knockdown of NOTCH ligands in hBMECs abrogated their ability to induce CSLC self-renewal and GBM tumor growth, both in vitro and in vivo (32-34). These findings establish that NOTCH activation in GBM

CSLCs is driven by signaling between tumor cells and their surrounding endothelial cells in the tumor microenvironment, suggesting that targeting both CSLCs and their vascular niche may provide a new way to deplete CSLCs and improve GBM treatment.

*Targeting of the MEK-ERK-MDM2-p53 pathway in combination with temozolomide*

Overcoming the resistance of glioblastoma cells against temozolomide a chemotherapeutic agent, is a major therapeutic challenge in the management of this tumor. The gene encoding O(6)-methylguanine DNA methyltransferase (MGMT), which removes the methyl group attached by temozolomide, is expressed in a significant fraction of glioblastomas and is therefore regarded as one of the mechanisms of resistance against temozolomide. Evidences show that the mitogen-activated protein/extracellular signal-regulated kinase (MEK)-extracellular signal-regulated kinase (ERK)--murine double minute 2 (MDM2)-p53 pathway plays a critical role in the regulation of MGMT expression. It has been shown that, in stem-like glioblastoma cells, MEK inhibition reduced MDM2 expression and that inhibition of either MEK or MDM2 resulted in p53 activation accompanied by p53-dependent downregulation of MGMT expression (35). MEK inhibition makes resistant stem-like glioblastoma cells sensitive to temozolomide, and combination of MEK inhibitor and temozolomide treatments effectively deprives stem-like glioblastoma cells of their tumorigenic potential.

*Antiglioma effects of oncolytic adenoviruses*

Antiglioma effect of the tumor-selective oncolytic adenovirus Delta-24-RGD has been previously reported (36). It has also been shown that Delta-24-RGD infects, replicates in, and induces cell death in brain tumor stem cells (BTSCs). Interestingly, adenoviral-infected cells undergo autophagy and that autophagy-related cytoplasmic vacuolization might be part of the lysis pro-

cess (37).

*Role of CD44v6 through the AKT-mediated pathway*

CD44 is a cell surface protein linked to tumorigenesis in various cancers. Patients with CD44 (high) GBM exhibited significantly poorer prognoses. Among various variant forms, CD44v6 is the only isoform that was detected in BTSC and its knock-down inhibited in vitro growth of BTSC from CD44 (high) GBM but not from CD44 (low) GBM (38). Stimulation with a CD44v6 ligand, osteopontin (OPN), increased expression of phosphorylated AKT in CD44 (high) GBM, but not in CD44 (low) GBM. In summary, data indicate that a subset of GBM expresses high CD44 in BTSC, and its growth may depend on CD44v6/AKT pathway.

*PFKFB4 as a key molecule is important for cancer cell survival*

RNA interference (RNAi) has been used to screen the complete human kinome and phosphatome (682 and 180 targets, respectively) in order to identify genes and pathways relevant for the survival of brain CSCs and thereby potential therapeutic targets for glioblastoma. 46 putative candidates have been reported including known survival-related kinases and phosphatases. A number of genes identified are involved in metabolism, especially glycolysis, such as PDK1 and PKM2 and, most prominently PFKFB4. Essential role of PFKFB4 in the maintenance of brain CSCs has been confirmed by in vitro studies (39). Additionally, high PFKFB4 expression is associated with shorter survival of primary glioblastoma patients (4). Findings support that glycolytic pathway is important in the maintenance of malignant glioma cells and brain CSCs and therefore tumor metabolism can be a promising therapeutic target in glioblastoma.

*Girdin and its role in the stemness of GSCs*

Hyperactivation of the PI3K-Akt path-

way, a pro-tumorigenic signaling cascade, is usually seen in GBM and contributes to its pathogenesis. Girdin (an actin-binding protein) that is a substrate of Akt, regulates the sprouting of axons and the migration of neural progenitor cells during early postnatal-stage neurogenesis in the hippocampus. Girdin is highly expressed in human glioblastoma (GBM). Stable Girdin knock-down in isolated GBM stem cells resulted in decreased expression of stem cell markers, including CD133, induced multilineage neural differentiation, and inhibited in vitro cell motility, ex vivo invasion and in vivo tumor formation. Furthermore, exogenous expression of the Akt-binding domain of Girdin, which competitively inhibits its Akt-mediated phosphorylation, diminished the expression of stem cell markers, SOX2 and nestin, and migration on the brain slice and induced the expression of neural differentiation markers glial fibrillary acidic protein/ $\beta$ III Tubulin (40). These results reveal that Girdin is required for GBM-initiating stem cells to sustain the stemness and invasive properties.

*Blockade of TGF- $\beta$  signaling by the TGF $\beta$ R-I Kinase Inhibitor LY2109761*

TGF- $\beta$  is a modifier of radiation response. Antitumor effects of the TGF- $\beta$  receptor (TGF $\beta$ R) I kinase inhibitor LY2109761 in combination with radiotherapy have been studied. In vivo studies show that LY2109761 reduces clonogenicity and increases radio-sensitivity in GBM cell lines and cancer stem-like cells and augments the tumor growth delay produced by fractionated radiotherapy in vivo. In an orthotopic intracranial model, LY2109761 significantly reduced tumor growth, and extended the prolongation of survival induced by radiation treatment. Histologic analyses showed that LY2109761 inhibited tumor invasion promoted by radiation and reduced tumor microvessel density. These results show that a selective inhibitor of the TGF $\beta$ R-I kinase can potentiate radiation responses in glioblastoma by coordinately increasing apoptosis and cancer stem-like

cells targeting while blocking DNA damage repair, invasion and angiogenesis (41). TGF $\beta$ R kinase inhibitors can be considered as radiosensitizers to improve the treatment of glioblastoma. There are some reports also which show that first-generation kinase inhibitors that selectively disrupt single kinases have failed to demonstrate clinical benefit in most patients with GBM. One strategy to solve this problem is to target multiple kinases by multitargeted kinase inhibitors or combinations of single targeted kinase inhibitors (42).

*PKC $\delta$  signaling and fractionated-radiation-induced expansion of glioma-initiating cells*

Reports have indicated that treatment of human glioma cells with fractionated radiation increases Abl (Abelson murine leukemia viral oncogene homolog) (Abl) and protein kinase C $\delta$  (PKC $\delta$ ) activity, expands the CD133-positive (CD133(+)) cell population that possesses tumor-initiating potential and induces expression of glioma stem cell markers and self-renewal-related proteins. Moreover, cells treated with fractionated radiation were resistant to anticancer treatments. Knock-down of PKC $\delta$  expression with small interfering RNA (siRNA) blocked fractionated-radiation-induced CD133(+) cell expansion and suppressed expression of glioma stem cell markers and self-renewal-related proteins. It also suppressed resistance of glioma cells to anticancer treatments. Similarly, knockdown of Abl leads to a decrease in CD133 (+) cell populations and restores chemotherapeutic sensitivity (43,44). Collectively, these data indicate that fractionated radiation induces an increase in the glioma-initiating cell population, decreases cellular sensitivity to cancer treatment and implicates activation of Abl-PKC $\delta$  signaling in both events. These findings might be important in the context of ionising-radiation-based therapeutic interventions for brain tumors.

*P53-deficient mouse astrocytes dedifferentiate into brain cancer stem-like cells by Nanog*

It has been reported that Nanog (a transcription factor critically involved with self-renewal of undifferentiated embryonic stem cells) has some role in the genesis of cancer stem-like cells. Evidences show that enforced Nanog expression can increase the cellular growth rate and transform phenotypes of p53-knockout astrocytes (p53(-/-) astrocytes), in vitro and in vivo (45,46). In addition, Nanog drives p53(-/-) astrocytes toward a dedifferentiated, CSC-like phenotype with characteristic neural stem cell/progenitor marker expression, self-renewal activity, and tumor formation (47,48). These findings suggest that dedifferentiation of p53-deficient mouse astrocytes into cancer stem-like cells can be promoted by Nanog.

*Effects of neural stem cells expressing TRAIL*

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF/nerve growth factor superfamily that induces cell death in susceptible cells (49). It can be found in two forms: membrane-bound (mTRAIL) and soluble protein. Glioma cells appeared to be more prone to apoptosis in co-culture with NSCs-mTRAIL than to treatment with soluble TRAIL. In vivo, the survival of animals possessing intracranial glial xenografts was significantly improved by NSCs-mTRAIL (50). These evidence demonstrate that therapy with NSCs-mTRAIL is effective in treatment of glioma.

*Hedgehog pathway*

The Hedgehog (Hh) pathway has a major regulatory role in many fundamental processes in vertebrate embryonic development including stem cell maintenance, cell differentiation and cell proliferation. This pathway also regulates proliferation of cancer stem cells and increases tumor invasiveness. inhibition of Hh signaling may be

effective in the treatment and prevention of many types of human cancers (51,52). Hh pathway inhibitors have significant clinical implications in novel cancer therapeutics. The oral compound, GDC-0449, is one of these inhibitors that has been shown to be effective and safe in Initial clinical trials (53,54).

*Role of matrix metalloproteinases (MMP) and their collagen substrates in cancer*

The MMP activity regulates the functionality of multiple extracellular matrix proteins, cytokines, growth factors and cell signaling and adhesion receptors. Enhanced MMP proteolysis affects multiple cell functions, including proliferation, migration and invasion. This aberrant MMP proteolysis is frequently seen in cancer. Collagen deposition, combined with an enhanced MMP activity in glioblastomas/gliomas, facilitates rapid invasion of tumor cells through the brain(55). It is hypothesized that mechanisms which control MMPs, TIMPs (MMPs tissue inhibitors) and collagens and, consequently, tumor cell invasion, may be promising drug targets and that in the near future these targets will be challenged pharmacologically.

*Role of YB-1 in differentiation & cell growth*

The Y-box binding protein 1 (YB-1) is essential for normal brain development, suggesting that YB-1 is part of a neural stem cell (NSC) network. It is also up regulated in many human malignancies including glioblastoma (GBM). Sox-2, nestin, and musashi-1 expression in the subventricular zone (SVZ) are reduced in YB-1 knockout mice. Although primary murine neurospheres were rich in YB-1, its expression is lost during glial differentiation. Silencing YB-1 with siRNA reduces neurosphere growth, and triggers differentiation. Furthermore, bone morphogenetic protein-4 suppresses YB-1 protein expression (56). Likewise, YB-1 expression is lost during differentiation of normal human NSCs. YB-1 correlatively expresses with NSC markers where it functions to promote

cell growth and inhibit differentiation.

#### *Nitric oxide synthase-2 and glioma stem cell proliferation*

It has been demonstrated that glioma stem cells (GSCs) produce nitric oxide via elevated nitric oxide synthase-2 (NOS2) expression. GSCs depend on NOS2 activity for growth and tumorigenicity, distinguishing them from non-GSCs and normal neural progenitors. High NOS2 expression correlates with decreased survival in human glioma patients, and NOS<sub>2</sub> inhibition slows glioma growth (57). These findings suggest that NOS<sub>2</sub> inhibition may be an effective approach to treat this devastating disease.

#### *Targeting $\beta$ III-Tubulin in Glioblastoma Multiforme*

Overexpression of  $\beta$ III-tubulin in GBM has been reported and it has been proposed that this aberrant expression may be linked to a disruption in microtubule dynamics associated with glioma tumorigenesis, tumor progression and transformation into GBM.  $\beta$ III-tubulin can be considered as a target of GBM therapy. Epothilones, a new family of anticancer agents, has been shown to be active in  $\beta$ III-tubulin-expressing tumor cells (58).

#### *Role of immunotherapy in GSCs*

The GSCs are resistant to resting natural killer (NK) cells because they express MHC class I molecules. However, lectin-activated NK cells kill GSCs. GSCs are also sensitive to antibody-mediated cytotoxicity. Sensitivity of GSC to cytotoxicity caused by IL2-activated NK cells and tumor-specific T cells has been shown. GSCs are more sensitive to NK and T cell-mediated lysis relatively to their corresponding serum-cultured GBM cells taken from the same initial tumor specimen (59). These results suggest that GSCs are suitable target cells for immunotherapy of GBM patients.

#### *Other factors*

The Oncostatin M (OSM) (a cytokine that belongs to the interleukin 6 group of cytokines.) and its receptor,

OsmR $\beta$ , are both expressed in the subventricular zone (SVZ). Osm can inhibit clonal growth of glioblastoma-derived neurospheres (60).

HOX genes encode a family of homeodomain-containing transcription factors involved in the determination of cell fate and identity during embryonic development. They also behave as oncogenes in some malignancies. It has been observed that HOXD9 protein is expressed in human brain tumor tissues, including astrocytomas and glioblastomas. Decreased cell proliferation and cell cycle arrest, have been observed when expression of HOXD9 protein is silenced by HOXD9-specific siRNA. It has been suggested that HOXD9 contributes to both cell proliferation and/or cell survival and can be a potential therapeutic target (61).

Maternal embryonic leucine-zipper kinase (MELK) has been identified as a key regulator of survival of stemlike GBM cells in vitro. It has been demonstrate that a thiazole antibiotic, siomycin A, potently reduces MELK expression and inhibits tumor growth in vivo. Treatment of stemlike GBM cells with siomycin A inhibits self-renewal (62).

Recent evidence have supported the importance of hypoxia in glioma stem cell (GSC) niches. Hypoxia-inducible factors (HIFs) hypothetically require epigenetic-modifying proteins to promote tumor malignancy in GBM (63). GSCs reside in a specialized hypoxic niche, which can regulate the tumorigenic capacity of GSCs primarily through HIFs (64).

Mesenchymal stem cells and/or neural stem cells were shown to target brain tumors, therefore these cells can be used as an effective delivery system to target and disseminate therapeutic agents to brain tumors.

Stem cell-based gene therapies for glioblastoma were shown in to be an effective way to target brain tumors.

BMP4 reduces proliferation of CD133 positive cells in vitro and the tumor growth in vivo and may act as a key inhibitory regulator (65).

## Conclusion

Brain tumors remain one of the most deadly cancers in adults, with an average period between diagnosis and death of ~12 months. The discovery of brain tumor stem cells and their chemo- and radioresistance have provided a reasonable explanation for the difficulty in these tumors treatment and the high rate of relapse. Indeed, as GBM cells are highly invasive, surgery is not routinely curative. In recent years targeting brain tumor stem cells opened up the way for new therapies. These new strategies in addition to other treatment approaches (gene therapy, immunotherapy) may show promising results to help patients with brain tumors.

## References

1. Khoshnevisan A, Muhammadnejad A, Muhammadnejad S, Mazaheri Z, Kazem haghghi M, et al. Establishment of Autochthonous & Standard Cell Line Derived Xenograft Models of Glioblastoma Multiform in Iran. *BCCR* 2011; 3(1):52-59.
2. Thangarajh M, Gutmann DH. Low-grade gliomas as neurodevelopmental disorders: Insights from mouse models of neurofibromatosis-1. *Neuropathol Appl Neurobiol* 2011 Oct 28;1365-2990.
3. Germano IM, Emdad L, Qadeer ZA, Binello E, Uzzaman M. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. *Cancer Gene Ther* 2010 Sep;17(9):664-74.
4. Zhou J, Shrikhande G, Xu J, McKay RM, Burns DK, Johnson JE, Parada LF. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. *Genes Dev.* 2011;25(15):1595-600.
5. Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. *Nat Rev Neurosci* 2011; 12(9):495-508.
6. Amanpour S, Muhammadnejad S, Muhammadnejad A, Mazaheri Z, Kazem-Haghghi M, Oghabian M, et al. Studying angiogenesis in autochthonous xenograft models of glioblastoma multiforme by MVD-CD34 technique in Iranian patients. *TUMJ* 2011; 69(3): 141-145.
7. He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, et al. CD90 is identified as a marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. *Mol Cell Proteomics*. In press.
8. Matos Rojas IA, Bertholdo D, Castillo M. Stem cells: implications in the development of brain tumors. *Radiologia*. In press.
9. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Genetic and epigenetic modifications of sox2 contribute to the invasive phenotype of malignant gliomas. *PLoS One*. 2011;6(11):e26740.
10. Yu SP, Yang XJ, Zhang B, Ming HL, Chen C, Ren BC, et al. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. *Chin Med J (Engl)* 2011;124(17):2599-604.
11. Sampetean O, Saga I, Nakanishi M, Sugihara E, Fukaya R, Onishi N, Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. *Neoplasia* 2011 Sep;13(9):784-91.
12. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. *Oncogene*. In press.
13. Svendsen A, Verhoeff JJ, Immervoll H, Brøgger JC, Kmiecik J, Poli A, et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. *Acta Neuropathol* 2011 Oct;122(4):495-510.
14. Lathia JD, Gallagher J, Myers JT, Li M, Vasanthi A, McLendon RE, et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. *PLoS One* 2011;6(9):e24807.
15. Deleyrolle LP, Harding A, Cato K, Siebzehnrbul FA, Rahman M, Azari H, Evidence for label-retaining tumour-initiating cells in human glioblastoma. *Brain* 2011 May;134(Pt 5):1331-43.
16. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. *Mol Cancer* 2007; 25(6):60.
17. Sun G, Ye P, Murai K, Lang MF, Li S, Zhang H, et al. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. *Nat Commun* 2011 Nov 8;2:529.
18. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. *PLoS One* 2011;6(9):e24584.
19. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Abounader R. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. *Cell Cycle* 2010 Mar, 15;9(6):1031-6.
20. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. *Oncogene* 2007, Jul;26(34):5017-22.
21. Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of



glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. *Biomaterials*. In press.

22. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. *Cancer Genomics Proteomics* 2011 May-Jun;8(3):139-47.

23. Sun H, Zhang S. Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. *Biochem Biophys Res Commun* 2011 Jul 8;410(3):692-7.

24. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. *Oncogene* 2005 Feb 3;24(6):980-91.

25. Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, Dugas JC, Gill RM, Huillard E, Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. *Oncogene*. In press.

26. He H, Niu CS, Li MW. Correlation between glioblastoma stem-like cells and tumor vascularization. *Oncol Rep* 2012 Jan;27(1):45-50.

27. Persano L, Rampazzo E, Della Puppa A, Pistollato F, Basso G. The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. *Scientific World Journal* 2011;11:1829-41.

28. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Iavernici G, Cenci T. Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* 2010 Dec, 468, 824-828.

29. Rahman M, Hoh BL. Glioblastoma multiforme tumor stem cells form endothelium. *World Neurosurg* 2011 Mar-Apr;75(3-4):338-9.

30. Shimizu F, Hovinga KE, Metzner M, Soulet D, Tabar V. Organotypic explant culture of glioblastoma multiforme and subsequent single-cell suspension. *Curr Protoc Stem Cell Biol* 2011 Dec; Chapter 3:Unit 3.5.

31. Turner JD, Sanai N. A brain tumor stem cell origin for glioblastoma endothelium. *World Neurosurg*. 2011 May-Jun;75(5-6):574-5.

32. Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. *Cancer Res*. 2011 Sep 15;71(18):6061-72.

33. Mei J, Bachoo R, Zhang CL. MicroRNA-146a inhibits glioma development by targeting Notch1. *Mol Cell Biol* 2011 Sep;31(17):3584-92.

34. Wang J, Wang C, Meng Q, Li S, Sun X, Bo Y, Yao W. siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. *Mol Biol Rep*. In press.

35. Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe, et al. E MEK-ERK Signaling Dictates DNA-Rep2air Gene MGMT Expression

and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis. *Stem Cells* 2011 Dec;29(12):1942-51.

36. Jiang H, Gomez-Manzano C, Lang F, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. *Curr Gene Ther* 2009 October; 9(5): 422-427.

37. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting brain tumor stem cells with oncolytic adenoviruses. *Methods Mol Biol* 2012; 797:111-25.

38. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. *PLoS ONE* 2011;6(9):e24217.

39. Altaner C. Glioblastoma and stem cells. *Neoplasma*. 2008;55(5):369-74.

40. Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, et al. Girdin maintains the stemness of glioblastoma stem cells. *Oncogene*. In press.

41. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettgenberg J, et al. Blockade of TGF- $\beta$  Signaling by the TGF $\beta$ R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma. *Cancer Res*. In press.

42. Sathornsumetee S. Therapeutic Strategies to Target Multiple Kinases in Glioblastoma. *Anti-cancer Agents Med Chem*. In press.

43. Kim MJ, Kim RK, Yoon CH, An S, Hwang SG, Suh Y, et al. Importance of PKC $\delta$  signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment. *J Cell Sci* 2011 Sep 15;124(Pt 18):3084-94.

44. Azoitei N, Kleger A, Schoo N, Thal DR, Brunner C, Pusapati GV, et al. Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. *Neuro Oncol* 2011 Jul;13(7):710-24.

45. Moon JH, Kwon S, Jun EK, Kim A, Whang KY, Kim H, et al. Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. *Biochem Biophys Res Commun* 2011 Aug 19;412(1):175-81.

46. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. *Cell* 2011 Jul 22;146(2):209-21.

47. Niu CS, Li DX, Liu YH, Fu XM, Tang SF, Li J. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. *Oncol Rep* 2011 Sep;26(3):593-601.

48. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. *EMBO J* 2010 Aug 4;29(15):2659-74.

49. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with

glioma xenografts. *Cancer Lett* 2011 Nov 28; 310(2):148-59

50. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. *Cancer Lett* 2011 Nov 28; 310(2):148-59.

51. Balbuena J, Pachon G, Lopez-Torrents G, Aran JM, Castresana JS, Petriz J. ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties. *Cytometry A* 2011 Sep;79(9):672-83.

52. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. *Cell Death Differ*. In press.

53. Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. *Ther Adv Med Oncol* 2010 Jul;2(4):237-50.

54. Wang X, Venugopal C, Manoranjan B, McFarlane N, O'Farrell E, Nolte S, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. *Oncogene*. In press.

55. Chernov AV, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. *Biomol Concepts* 2011 Jun;2(3):135-147.

56. Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. *Cancer Res* 2011 Aug 15;71(16):5569-78.

57. Eyler CE, Wu Q, Yan K, MacSwords JM,

Chandler-Militello D, Misuraca KL, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. *Cell* 2011 Jul 8; 146(1):53-6.

58. Katsetos CD, Dráber P, Kavallaris M. Targeting III-Tubulin in Glioblastoma Multiforme: From Cell Biology And Histopathology To Cancer Therapeutics. *Anticancer Agents Med Chem*. In press.

59. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, et al. Human Glioblastoma Stem-Like Cells are More Sensitive to Allogeneic NK and T Cell-Mediated Killing Compared with Serum-Cultured Glioblastoma Cells. *Brain Pathol*. In press.

60. Beatus P, Jhaveri DJ, Walker TL, Lucas PG, Rietze RL, Cooper HM, et al. Oncostatin M regulates neural precursor activity in the adult brain. *Dev Neurobiol* 2011 Jul;71(7):619-33.

61. Tabuse M, Ohta S, Ohashi Y, Fukaya R, Misawa A, Yoshida K, et al. Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. *Mol Cancer* 2011 May 22;10:60.

62. Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, et al. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. *Neuro Oncol* 2011;13(6):622-34

63. Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. *Cell Death Differ*. In press.

64. Mao XG, Yan M, Xue XY, Zhang X, Ren HG, Guo G, et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. *Lab Invest* 2011 Jul;91(7):1068-78

65. Altaner C. Glioblastoma and stem cells. *Neoplasma* 2008;55(5):369-74.